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BACKGROUND: The benefits of routine invasive management in patients 
with prior coronary artery bypass grafts presenting with non-ST elevation 
acute coronary syndromes are uncertain because these patients were 
excluded from pivotal trials.
METHODS: In a multicenter trial, non-ST elevation acute coronary syndromes 
patients with prior coronary artery bypass graft were prospectively screened 
in 4 acute hospitals. Medically stabilized patients were randomized to 
invasive management (invasive group) or noninvasive management 
(medical group). The primary outcome was adherence with the randomized 
strategy by 30 days. A blinded, independent Clinical Event Committee 
adjudicated predefined composite outcomes for efficacy (all-cause mortality, 
rehospitalization for refractory ischemia/angina, myocardial infarction, 
hospitalization because of heart failure) and safety (major bleeding, stroke, 
procedure-related myocardial infarction, and worsening renal function).
RESULTS: Two hundred seventeen patients were screened and 60 (mean±SD 
age, 71±9 years, 72% male) were randomized (invasive group, n=31; medical 
group, n=29). One-third (n=10) of the participants in the invasive group 
initially received percutaneous coronary intervention. In the medical group, 1 
participant crossed over to invasive management on day 30 but percutaneous 
coronary intervention was not performed. During 2-years’ follow-up (median 
[interquartile range], 744 [570–853] days), the composite outcome for efficacy 
occurred in 13 (42%) subjects in the invasive group and 13 (45%) subjects 
in the medical group. The composite safety outcome occurred in 8 (26%) 
subjects in the invasive group and 9 (31%) subjects in the medical group. 
An efficacy or safety outcome occurred in 17 (55%) subjects in the invasive 
group and 16 (55%) subjects in the medical group. Health status (EuroQol 5 
Dimensions) and angina class in each group were similar at 12 months.
CONCLUSIONS: More than half of the population experienced a serious 
adverse event. An initial noninvasive management strategy is feasible. 
A substantive health outcomes trial of invasive versus noninvasive 
management in non-ST elevation acute coronary syndromes patients with 
prior coronary artery bypass grafts appears warranted.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. 
Unique identifier: NCT01895751.
VISUAL OVERVIEW: A visual overview is available for this article.
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MBChB et al
ORIGINAL ARTICLE
Invasive Versus Medical Management  in Patients 
With Prior Coronary Artery Bypass Surgery With a 
Non-ST Segment Elevation Acute Coronary Syndrome
A Pilot Randomized Controlled Trial
© 2019 The Authors. Circulation: 
Cardiovascular Interventions is 
published on behalf of the American 
Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open 
access article under the terms of the 
Creative Commons Attribution License, 
which permits use, distribution, and 
reproduction in any medium, provided 
that the original work is properly cited.
https://www.ahajournals.org/journal/
circinterventions
Circulation: Cardiovascular Interventions
June62019
D
ow
nloaded from
 http://ahajournals.org by on August 5, 2019
Lee et al; Invasive Versus Medical Care in the CABG-ACS Trial
Circ Cardiovasc Interv. 2019;12:e007830. DOI: 10.1161/CIRCINTERVENTIONS.119.007830 August 2019 2
Based on the results of 10 randomized trials of invasive versus conservative medical manage-ment in patients with a non-ST segment elevation 
acute coronary syndrome (NSTE-ACS1,2; Table 1),3–18 inva-
sive management is associated with a Class 1 practice 
guideline recommendation (Level of Evidence A).19–21 
Around 1 in 10 patients admitted to hospital with an 
acute NSTE-ACS have a history of prior coronary artery 
bypass graft surgery (CABG).19–22 CABG is a standard 
of care for patients with obstructive coronary artery 
disease; however, reflecting the natural history of 
saphenous vein graft disease, graft occlusion is com-
mon within 10 years of surgery.23–25 Patients with prior 
CABG have a progressive longer-term risk of recurrent 
ischemia, including angina (>6% at 1 year),26 myo-
cardial infarction (MI; >7% after 6 years,27 or >10% 
within 10 years),28 hospitalization for heart failure (HF; 
2% within 30 days),29 and death (>2% at 1 year30,31 
rising to >4% to 9% after 5 years).22,27,32,33 This group 
of patients presents a challenge to healthcare provid-
ers globally not least because of their elderly age and 
multimorbidity.
Some of the pivotal trials of invasive versus conser-
vative management in NSTE-ACS, including throm-
bolysis in myocardial ischemia,15 FRagmin and Fast 
Revascularisation during InStability in Coronary artery 
disease,34 and RITA 3 (Randomized Intervention Trial of 
unstable Angina),18 excluded patients with prior CABG 
(Table 1). Therefore, the relevance of practice guideline 
recommendations19,20,35 and balance of risks and ben-
efits in this large subgroup of patients is less certain.36–38 
When invasive management is performed, revascular-
ization with either percutaneous coronary intervention 
(PCI) or redo CABG is less likely in NSTE-ACS patients 
with prior CABG.37–40 However, advances in percutane-
ous revascularization techniques create new therapeu-
tic possibilities for this patient group.
A substantive, health outcome trial of invasive man-
agement involving contemporary techniques versus 
noninvasive management appears warranted. However, 
critical uncertainties relating to the feasibility of enroll-
ment, adherence to the randomized strategy, and over-
all safety undermine the rationale for such a trial.
In this study, we aimed to assess the feasibility and 
safety of routine noninvasive versus invasive manage-
ment in patients with NSTE-ACS and prior CABG in a 
multicenter setting. To address this aim, we undertook 
a randomized, controlled, pilot trial of routine invasive 
management (standard of care) versus noninvasive 
medical management. The primary hypothesis was 
that in patients with NSTE-ACS and prior CABG ran-
domization to medical management is routinely fea-
sible, as reflected by adherence to this strategy by 30 
days. Evidence of efficacy and safety in the longer term 
was prospectively assessed. The efficacy of each strat-
egy was assessed by blinded assessment of all-cause 
mortality, nonfatal MI, or hospitalization for HF events 
during longer-term follow-up. The safety of each strat-
egy was assessed by comparison of bleeding (Bleeding 
Academic Research Consortium types 2–4),41 stroke, 
procedure-related MI (Type 4a, European Society of 
Cardiology Universal Definition of MI),42 and worsening 
renal function or hemodialysis events during the index 
hospitalization.
METHODS
The data that support the findings of this study are available 
from the corresponding author on reasonable request.
Study Design and Setting
The design of this pilot trial has been previously described.12 
The participants were enrolled in 4 acute hospitals in the 
National Health Service (NHS), United Kingdom, including 2 
large urban hospitals (Western Infirmary and Royal Infirmary, 
Glasgow) and 2 regional hospitals (Royal Alexandra Hospital, 
Paisley and Royal Blackburn Hospital). More details about 
these hospitals are detailed in the Data Supplement.
Population
Eligibility for randomization in the trial was based on the fol-
lowing criteria:
WHAT IS KNOWN
• There is an evidence gap on the safety and effi-
cacy of invasive management in patients with a 
prior coronary artery bypass graft because they 
were excluded from several clinical trials of rou-
tine invasive management versus conservative 
management.
WHAT THE STUDY ADDS
• In a randomized, multicenter trial, we obtained 
proof-of-concept information on feasibility, effi-
cacy, and safety of routine medical management 
compared with invasive management in medically 
stabilized patients following an acute non-ST seg-
ment elevation acute coronary syndrome and a 
history of prior coronary artery bypass grafts.
• Health outcomes and quality of life during a 
median of over 2-years follow-up were similar for 
patients in each group.
• In the invasive group, percutaneous coronary inter-
vention was performed in one-third of the partici-
pants while in the medical group, only 1 (3.4%) 
participant crossed over to invasive management 
on day 30 but percutaneous coronary intervention 
was not performed.
• A comparative effectiveness trial involving con-
temporary invasive and medical therapies seems 
justified.
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Inclusion
(1) Unstable angina or non-ST segment elevation MI; (2) sta-
bilized symptoms without recurrent chest pain or intravenous 
therapy for 12 hours; (3) prior CABG.
Exclusion
(1) Refractory ischemia (ie, recurrent angina with minimal 
exertion or at rest [ie, Canadian Cardiovascular Society class 
III or IV] not controlled by medical therapy); (2) cardiogenic 
shock; (3) lack of informed consent; (4) unsuitable for invasive 
management.
Patients who fulfilled the eligibility criteria were pro-
vided with an information sheet as soon as feasible 
after hospital admission and before referral for coronary 
angiography. Written informed consent was required for 
participation in the trial.
Screening
The clinical research team on each site screened patients who 
had been hospitalized during unscheduled emergency care. 
Patients who were 18 years and older, of either sex, and who 
had a history of NSTE-ACS and prior CABG were prospectively 
identified. Trial participation required that the attending phy-
sician confirm there was equipoise for the potential benefits 
of either invasive management or noninvasive management. 
If either the physician or the patient did not agree, then the 
patient was designated as a screen failure. Informed consent 
for participation in the follow-up registry was then invited. 
Each patient was assigned a unique study number and then 
entered into a screening log. The community health index or 
NHS number was recorded to enable electronic record linkage 
using routinely collected NHS datasets.
Randomization
Patients who fulfilled the inclusion criteria and did not have 
any exclusion criteria and who also had provided written 
informed consent were enrolled into the trial. Randomization 
was performed using an interactive voice recognition system 
managed by the Glasgow Clinical Trials Unit. Participants 
were randomized 1:1 to either the invasive group or medical 
group. Randomization was stratified by center, using random-
ized permuted blocks of length 4 and 6, with block lengths 
chosen at random.
Medical Therapy
Optimal medical therapy was recommended for participants 
in both of the randomized groups. Guidance on uptitration of 
medical therapy in both groups was provided in an investiga-
tor guideline. Medical therapy included dual antiplatelet, anti-
thrombotic, and antianginal therapies as per local protocols 
and international guidelines.19,20
Medical Group
According to the trial protocol, study participants who had 
been randomized to the medical group, that is, noninva-
sive management, could be referred for invasive manage-
ment if prespecified criteria (Data Supplement) occurred 
post-randomization.
Invasive Group
Invasive management was performed early (ie, ≤72 hours 
wherever possible) after hospital admission. Invasive manage-
ment included native coronary and bypass graft angiography 
and coronary and graft revascularization with percutaneous 
coronary intervention and CABG, as clinically appropriate.
Screen Failures
Screened patients who were (1) eligible but did not consent 
to participate in the randomized trial or (2) did not meet eligi-
bility criteria (Figure 1; CONSORT [Consolidated Standards of 
Reporting Trials] diagram) were included in a screen failure log.
Table 1. Trials of Patients With Non-ST Elevation Acute Coronary 
Syndromes
Trials Which Included Patients With Prior CABG  
Trial
Year 
Published N
N (%) With Prior 
CABG
  VANQWISH3 1998 920 156 (17.0%)*
  MATE4 1998 201 19 (9.5%)
  TRUCS5 2000 148 18 (12.2%)
  TACTICS-TIMI 186 2001 2220 484 (21.8%)†
  ISAR-COOL7 2003 410 48 (11.7%)
  ICTUS8 2005 1200 105 (8.8%)
  OASIS-59 2009 20 078 1643 (8.2%)
  LIPSIA-NSTEMI10 2012 600 41 (6.8%)
  Italian elderly ACS11 2012 313 29 (9.3%)
  CABG-ACS pilot12 2016 60 60 (100.0%)
  After Eighty Study13 2016 457 76 (16.6%)
  MOSCA14 2016 106 14 (13.2%)
Trials which excluded patients with prior CABG
Trial
Year 
published N Exclusion
  TIMI IIIB15 1994 1473 CABG at any time
  FRISC II16 1999 2457 Previous open-heart 
surgery
  VINO17 2002 131 CABG < 6 mo
  RITA 318 2002 1810 CABG at any time
ACS indicates acute coronary syndrome; CABG, coronary artery bypass 
graft; FRISC II, Fragmin and Fast Revascularisation During Instability in Coronary 
Artery Disease; ICTUS, Invasive Versus Conservative Treatment in Unstable 
Coronary Syndromes; ISAR-COOL, Intracoronary Stenting With Antithrombotic 
Regimen Cooling-Off; LIPSIA-NSTEMI, The Leipzig Immediate Versus Early and 
Late Percutaneous Coronary Intervention Trial in NSTEMI; MATE, Medicine 
Versus Angiography in Thrombolytic Exclusion; MOSCA, Comorbilidades en el 
Síndrome Coronario Agudo; OASIS-5, Fifth Organization to Assess Strategies 
in Ischemic Syndromes; RITA 3, Randomized Intervention Trial of Unstable 
Angina; TACTICS-TIMI 18, Treat Angina With Aggrastat and Determine 
Cost of Therapy With an Invasive or Conservative Strategy—Thrombolysis 
in Myocardial Infarction 18; TIMI IIIB, Thrombolysis in Myocardial Ischemia; 
TRUCS, Treatment of Refractory Unstable Angina in Geographically Isolated 
Areas Without Cardiac Surgery; VANQWISH, Veterans Affairs Non-Q-Wave 
Infarction Strategies in Hospital; and VINO, Value of First Day Angiography/
Angioplasty in Evolving Non-ST Segment Elevation Myocardial Infarction: An 
Open Multicenter Randomized Trial.
*CABG >3 mo before randomization.
†CABG >6 mo before randomization. 
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Registry
The reasons for nonparticipation of patients who were eligi-
ble for randomization were prospectively recorded: physician 
preference, patient preference, or both (Figure 1; CONSORT 
diagram).
Follow-Up
Clinical research nurses and physicians who were indepen-
dent of the study teams and aware of the group allocations 
conducted the follow-up assessments. They prospectively 
gathered information on screening, recruitment, randomiza-
tion (to medical therapy or invasive management), crossover 
rates, and serious adverse events in patients with prior CABG 
and a recent NSTE-ACS.
Sample Size
The sample size of 60 randomized participants was prede-
termined to be sufficient to provide information on the fea-
sibility of randomization in a consecutive series of patients 
with NSTE-ACS and prior CABG who had been prospectively 
enrolled, ad hoc, during unscheduled care. The sample size 
was also intended to be sufficient to provide information on 
adherence with the allocated strategy within the first 30 days. 
The trial was not powered to assess for between-group differ-
ences in the rates of the serious adverse events contributing 
to the prespecified efficacy and safety outcomes.
Outcomes
Serious adverse events during the index admission and follow-
up were detected by contacting the participants at 6- and 12 
months following enrollment, by reviewing medical records 
obtained during usual care, and routinely collected electronic 
health databases, including the community health index 
number and NHS number. The occurrence of these outcomes 
was prospectively entered into an electronic case report form.
Primary Outcome
The primary outcome was the postrandomization rate of 
major adverse events (coprimary composite outcome), includ-
ing 1 composite outcome for efficacy and 1 composite out-
come for safety. The comparison between the incidences of 
each outcome according to treatment group assessed the 
between-group difference in the proportion of major adverse 
Figure 1. CONSORT flow diagram.  
CABG indicates coronary artery bypass graft.
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events in patients allocated to noninvasive conservative man-
agement compared with invasive management.
Primary Efficacy Outcome
Defined as all-cause mortality, rehospitalization for refractory 
ischemia/angina, MI, or hospitalization for HF. The end points 
were assessed during the study until the final randomized 
patient had completed 18 months follow-up.
Primary Safety Outcome
Defined as bleeding (bleeding academic research consor-
tium types 2–4),41 stroke, procedure-related MI (Type 4a, 
European Society of Cardiology Universal Definition of MI),42 
worsening renal function, or hemodialysis during the index 
hospitalization.
Secondary Outcomes
1. Quality of life
 EuroQol 5 Dimensions 5 Levels and EuroQol Visual 
Analogue Scale were assessed at baseline and 6 monthly 
intervals for a minimum of 18 months.
2. Canadian Cardiovascular Society angina class
3. Hospitalization for refractory ischemia
 The definition of refractory ischemia is detailed in the 
Data Supplement.
4. Invasive management during follow-up
5. Coronary and bypass graft intervention during follow-up
Clinical Event Committee
An independent Clinical Event Committee (CEC) reviewed 
serious adverse events that potentially fulfilled the defini-
tion of a primary outcome event. The CEC was blinded to 
all information relating to the randomization group. The CEC 
reviewed cases of interest to determine if they met the crite-
ria defined in the prespecified charter. Causality assessments 
were not made by the CEC. The CEC included 4 cardiovascu-
lar physicians with expertise in the diagnosis and treatment of 
cardiovascular disorders and in the medical aspects of clinical 
trials. The CEC included a Chair (M.C. Petrie) and a coordina-
tor (M.M.Y. Lee) to assist with preparation of de-identified 
source clinical data, reports, and communication with the 
clinical trials unit. The CEC followed a predetermined adju-
dication charter.
Definitions of Adverse Events
The adverse events of death, procedure-related MI, stroke, 
major bleeding, and worsening renal function are defined as 
detailed in the Data Supplement.
Follow-Up and Timing of Outcome 
Evaluations
Follow-up (via telephone contact, clinic visits, letter) with com-
pletion of quality of life assessments (EuroQol 5 Dimensions 5 
Levels and EuroQol Visual Analogue Scale ) was maintained at 
6 monthly intervals until a minimum of 18 months follow-up 
had been reached for the final recruited patient. Consent was 
obtained for long-term follow-up analyses.
Following randomization, clinical assessments involved 
gathering information from the standard of care clinical 
reviews (end of hospitalization, 30–42 days, and 1 year) and 
also from clinical contacts recorded in the patients’ medical 
records. In West of Scotland hospitals, a single system of elec-
tronic patient records is used for all hospital attendances and 
correspondence with primary care.
Crossover
A crossover from 1 randomized group to another was pre-
defined as a change of treatment strategy from invasive to 
noninvasive management or vice versa within 30 days of ran-
domization. While the intention-to-treat in each group was 
either with noninvasive or invasive management, all treat-
ment options remained available according to patient and 
physician preference, that is, patients initially randomized to 
medical therapy could have undergone invasive management 
and vice versa. No additional interventions were proposed nor 
were procedures withdrawn that would be needed on clinical 
grounds.
Data Management and Biostatistics
The Robertson Centre for Biostatistics acted as an independent 
coordinating center for randomization, data management, 
and statistical analyses. The Centre is part of the registered 
Glasgow Clinical Trials Unit (National Institute for Health 
Research Registration number: 16). The Chief Investigator (Dr 
Berry) had full access to all the data in the study and takes 
responsibility for its integrity and the data analysis
Statistical Analysis
Baseline characteristics of the randomized participants were 
summarized by group using mean (SD), or median (lower 
quartile, upper quartile for skewed data) for continuous vari-
ables and count (%) for categorical variables. Numbers of 
events and numbers of patients with events were summa-
rized. Time to occurrence of the primary efficacy and safety 
outcomes was summarized using Kaplan-Meier survival 
curves. Cox models were fitted to the time to primary effi-
cacy outcome, primary safety outcome, both primary efficacy 
and safety outcomes and either primary efficacy or safety out-
come and the differences between the Invasive and Medical 
Groups presented as hazard ratios (HRs) and corresponding 
95% CIs. Descriptive statistics only were produced for the 
secondary outcomes because of the study being a pilot trial 
and not adequately powered for hypothesis testing for these 
outcomes.
Ethics
The research study was reviewed and approved by the 
West of Scotland NHS Research Ethics Service (Reference 
11-WS-0116).
Trial Management
A Trial Management Group including the researchers and 
Local Principal Investigator on each of the 4 sites coordinated 
the study’s activities on a day-to-day basis.
The NHS Sponsor monitored the trial. Since the trial was a 
pilot, there was no Independent Data and Safety Monitoring 
Committee.43
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RESULTS
Two hundred seventeen patients with an unplanned 
hospitalization for a confirmed or suspected NSTE-
ACS and a history of prior CABG were screened dur-
ing a 16-month period. The first patient was enrolled 
on February 20, 2012 (Figure 1; CONSORT diagram). 
Eighty-four (39%) of these patients were screen fail-
ures, including 24 (29%) who did not give consent and 
60 (71%) who were ineligible (≥1 reason). The rea-
sons for being ineligible included lack of a confirmed 
NSTE-ACS (n=42 [70%] patient), persisting unstable 
symptoms (n=39 [65%] patients), refractory ischemia 
(n=5 [8%] patients), unsuitable for invasive manage-
ment (n=22 [37%] patients), no prior CABG (n=4 [7%] 
patients), and unable to provide informed consent (n=3 
[5%] patients).
Table 2. Baseline Clinical and Angiographic Characteristics of the Trial 
Participants
Characteristic
All 
(N=60)
Invasive 
(N=31)
Medical 
(N=29)
Age, y* 71±9 69±10 73±8
Female 17 (28%) 7 (23%) 10 (34%)
Obesity (BMI >30 kg/m2) 22 (37%) 12 (39%) 10 (34%)
NSTEMI 41 (68%) 21 (68%) 20 (69%)
Unstable angina 19 (32%) 10 (32%) 9 (31%)
Diabetes mellitus† 21 (35%) 10 (32%) 11 (38%)
Previous myocardial 
infarction
41 (68%) 23 (74%) 18 (62%)
Cardiac arrhythmia 19 (32%) 12 (39%) 7 (24%)
Hypertension history 42 (70%) 23 (74%) 19 (66%)
Peripheral vascular 
disease
16 (27%) 11 (35%) 5 (17%)
Cerebrovascular disease 13 (22%) 7 (23%) 6 (21%)
Congestive cardiac failure 14 (23%) 9 (29%) 5 (17%)
Renal impairment history 13 (22%) 9 (29%) 4 (14%)
Creatinine concentration‡ 84 (68–101) 91 (70–107) 83 (67–95)
Chronic anemia 5 (8%) 3 (10%) 2 (7%)
Hemoglobin (g/L)* 135±16 136±17 135±16
Valve disease 12 (20%) 5 (16%) 7 (24%)
Pacemaker 5 (8%) 3 (10%) 2 (7%)
Smoking history
  Current 12 (20%) 7 (23%) 5 (17%)
  Ex (stopped >3 mo) 33 (55%) 20 (65%) 13 (45%)
  Never 15 (25%) 4 (13%) 11 (38%)
Charlson comorbidity 
index‡
4 (3–6) 4 (3–8) 4 (3–5)
ST-segment depression 28 (47%) 14 (45%) 14 (48%)
ST-segment elevation 11 (18%) 8 (26%) 3 (10%)
T-wave inversion 38 (63%) 20 (65%) 18 (62%)
Q-waves 15 (25%) 9 (29%) 6 (21%)
Left bundle branch block 5 (8%) 3 (10%) 2 (7%)
Right bundle branch block 3 (5%) 1 (3%) 2 (7%)
Atrial fibrillation or flutter 9 (15%) 5 (16%) 4 (14%)
New ischemic ECG 
changes§
30 (50%) 19 (61%) 11 (38%)
CCS angina class‖
  I 2 (3%) 0 (0%) 2 (7%)
  II 6 (10%) 4 (13%) 2 (7%)
  III 10 (17%) 4 (13%) 6 (21%)
  IV 41 (69%) 22 (73%) 19 (66%)
Left internal mammary 
artery graft
50 (83%) 27 (87%) 23 (79%)
Saphenous vein graft
  0 3 (5%) 2 (6%) 1 (14%)
  1 17 (29%) 6 (19%) 11 (41%)
  2 25 (43%) 16 (52%) 9 (33%)
(Continued )
  ≥3 13 (22%) 7 (23%) 6 (22%)
Frailty score
  Fit or well (1, 2, 3) 35 (58%) 15 (48%) 20 (69%)
  Vulnerable (4) or 
mildly frail (5)
14 (23%) 9 (29%) 5 (17%)
  Moderately frail (6) 10 (17%) 6 (19%) 4 (14%)
  Severely frail (7) 1 (2%) 1 (3%) 0 (0%)
Health-related quality of 
life, EQ-5D-5L score
0.748 
(0.514–0.899)
0.602 
(0.360–0.881)
0.863 
(0.596–0.924)
Medical therapy
  Aspirin 52 (87%) 29 (94%) 23 (79%)
  Statin 55 (92%) 29 (94%) 26 (90%)
  β-Blocker 42 (70%) 21 (68%) 21 (72%)
  Calcium channel 
blocker
60 (100%) 31 (100%) 29 (100%)
  Isosorbide mononitrate 20 (33%) 12 (39%) 8 (28%)
  Nicorandil 22 (37%) 15 (48%) 7 (24%)
  ACE-inhibitor 50 (83%) 27 (87%) 23 (79%)
  Insulin 10 (17%) 6 (19%) 4 (14%)
  Oral antidiabetic 
therapy
10 (17%) 5 (16%) 5 (17%)
  Antidepressant 
therapy
13 (22%) 8 (26%) 5 (17%)
  Diuretic 18 (30%) 8 (26%) 10 (34%)
  Polpharmacy (≥4 
medicines)
57 (95%) 30 (97%) 27 (93%)
ACE indicates angiotensin-converting enzyme; BMI, body mass index; CCS, 
Canadian Cardiovascular Society; EQ-5D-5L, EuroQol 5 Dimensions 5 Levels; 
and NSTEMI, non–ST-segment–elevation myocardial infarction.
*Mean±SD.
†Diabetes mellitus was defined as a history of diet-controlled or treated 
diabetes mellitus.
‡Median (interquartile range).
§Any previous episodes with new ischemic ECG changes.
‖The highest CCS value of any previous episode for each patient.
Table 2. Continued
Characteristic
All 
(N=60)
Invasive 
(N=31)
Medical 
(N=29)
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One hundred thirty-three (61%) subjects fulfilled eli-
gibility criteria for the randomized trial (Figure 1) and 
60 (mean±SD, 71±9 years of age, 43 [72%] male) were 
enrolled into the trial and randomized. Seventy-three 
(mean±SD, 72±10 years of age, 53 [73%] male) patients 
who were eligible for the trial were not randomized 
Figure 2. Clinical case.  
A 51-y-old male was hospitalized following an acute non-ST elevation acute coronary syndrome. A, Twelve-lead ECG demonstrated atrial fibrillation with ST 
depression and T-wave inversion in the lateral leads, which were not significantly changed from previous ECGs. The Global Registry of Acute Coronary Events score 
for death or myocardial infarction within 6 mo was 107. The past medical history included coronary artery bypass grafting 14 y previously, left ventricular systolic 
dysfunction, a cardiac defibrillator for primary prevention, and atrial fibrillation. The surgical record and graft history were not available. The day after admission to 
hospital, the patient provided written informed consent to participate in the CABG-ACS (coronary artery bypass graft acute coronary syndrome) trial, and he was 
randomized to the invasive group. Coronary angiography was performed on an urgent basis via the left radial artery. B, The native left main coronary artery was 
occluded at the ostium (white arrow). C, The saphenous vein grafts to the right coronary artery (RCA; red arrow) and obtuse marginal branch of the left coronary 
artery (orange arrow) were also occluded. D, Angiography of the native RCA revealed proximal and mid-vessel occlusions associated with bridging ipsilateral col-
lateral connections (green arrow). E, The left internal mammary artery (LIMA) graft had a 70% to 80% stenosis (dark red arrow) involving the anastomosis with 
the left anterior descending (LAD) coronary artery with normal antegrade flow. This lesion was judged to be the culprit. The LIMA supplied collaterals to the distal 
branches of the RCA pointing to a large territory of jeopardized myocardium. Given the history of left ventricular dysfunction, the ischemic area-at-risk, and risks 
of percutaneous coronary intervention (PCI) to this stenosis, the treatment plan was for deferred management including uptitration of antiangina drug therapy and 
PCI to the LIMA should symptoms became refractory. F, Two mo later, the patient was readmitted because of persistent angina, and PCI to the insertional stenosis 
of the LIMA-LAD anastomosis stenosis was then performed (yellow arrow). Following predilatation, a 3.0×28 mm drug eluting stent was deployed at 17 atm. PCI 
was completed with high inflation postdilatation and an excellent final result was obtained. G, Angiography at the end of the procedure revealed antegrade filling 
of the distal LAD and retrograde filling of the posterior descending branch of the RCA via collateral connections from the LIMA-LAD system (light green arrow). 
Dual antiplatelet therapy was prescribed for 12 mo. The patient was hospitalized on 3 further occasions. He experienced a type 1 non-ST elevation myocardial 
infarction 4 mo later. In-stent restenosis was diagnosed and treated with additional PCI. Two mo later, he was then hospitalized with unstable angina and 2 mo 
after that he experienced another type 1 NSTEMI. He was medically managed on these occasions.
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because of physician preference (n=58), patient pref-
erence (n=28), or both (n=15). The mean ages of the 
patients in the registry (72±10 years) and trial groups 
(71±9 years) were similar (P=0.46), as were the propor-
tions of women (20 [27%] versus 17 [28%]; P=1.00).
Baseline Characteristics
The characteristics of the trial participants are 
described in Table 2 and a clinical case is illustrated 
in Figure 2. The mean age was 71 years, and all of 
the participants had at least 1 concomitant health 
problem. Multimorbidity was very common (Table 2). 
Two thirds had a history of hypertension, one-third 
had diabetes mellitus, one-quarter had HF, and one-
fifth had cerebrovascular disease or renal failure. 
The sample averages and rates of other comorbidi-
ties, age, sex, Charlson Comorbidity Index, Canadian 
Cardiovascular Society grade, frailty score, and medi-
cations were broadly similar between the groups. Fifty 
(83%) of the trial participants had a history of a left 
internal mammary artery graft.
Medical Therapy
Changes in secondary preventive medications and 
antianginal therapy during the index hospitalization 
were prescribed in the majority of participants, and the 
changes in medical therapy were similar in each group 
(Table 3).
Invasive Management
Invasive management was performed in all 31 partici-
pants in the invasive group (Table 4). Percutaneous coro-
nary intervention was performed in 10 (32%) participants 
in the invasive group during the index hospitalization 
and 4 more patients in this group received PCI during a 
second procedure as part of a staged management plan 
(n=14 [45%], overall). The mean British Cardiovascular 
Intervention Society-1 Jeopardy Score at baseline in 
the Invasive Group pre- and post-PCI was 4.3±3.7 and 
2.4±2.5, respectively, out of a possible maximum score 
of 12 (Table 4). During follow-up (≥18 months), 39 coro-
nary angiogram procedures were performed in the inva-
sive group (including 17 [44%] proceeding to PCI).
In the medical group, 1 male patient crossed over 
to invasive management on day 30 postrandomization 
because of recurrent angina. No revascularization targets 
were identified by coronary and graft angiography and 
Table 3. Reasons for Changing Medical Therapy During the Index 
Hospitalization
Reason
All 
(N=60)
Invasive 
(N=31)
Medical 
(N=29)
Recurrent angina 13 (22%) 9 (29%) 4 (14%)
Standard optimization of 
secondary preventive therapy
54 (90%) 26 (84%) 28 (97%)
Standard optimization of 
antianginal therapy
54 (90%) 29 (94%) 25 (86%)
Intolerant of medication 
without adverse reaction
2 (3%) 1 (3%) 1 (3%)
Side effect/adverse reaction 2 (3%) 1 (3%) 1 (3%)
Other 3 (5%) 1 (3%) 2 (7%)
Table 4. Invasive Procedures at Baseline (Index Admission) and 
Follow-Up (≥18 Months)
Subjects With Procedures at Baseline 
and Follow-Up
Invasive 
(N=31)
Medical 
(N=15)
  Subjects with 1 procedure 25 (81%) 12 (80%)
  Subjects with 2 procedures 5 (16%) 3 (20%)
  Subjects with 3 procedures 0 (0%) 0 (0%)
  Subjects with 4 procedures 1 (3%) 0 (0%)
  Subjects with PCI at baseline 10 (32%) 0 (0.0%)
  Subjects with PCI at baseline and follow-up 14 (45%) 7 (47%)
Days from randomization to subject’s first 
procedure*
13 (4–24) 86 (58–191)
  <30 days 25 (81%) 0 (0%)
  30–59 days 4 (13%) 5 (33%)
  ≥60 days 2 (6%) 10 (67%)
Procedures at baseline Invasive 
(N=31)
Medical 
(N=0)
  BCIS-1 Jeopardy Score (pre-PCI) at baseline† 4.3±3.7 …
  PCI at baseline 10 (32%) …
  BCIS-1 Jeopardy Score (post-PCI) at 
baseline†
2.4±2.5 …
Procedures at baseline and follow-up Invasive 
(N=39)
Medical 
(N=18)
  Urgent in-patient procedure 16 (41%) 11 (61%)
  Outpatient procedure 23 (59%) 7 (39%)
  Hospitalization‡ 17 (44%) 11 (61%)
  Complications related to angiogram§ 1 (3%) 0 (0%)
  Culprit vessel unknown 18 (46%) 9 (50%)
  Culprit vessel identified 21 (54%) 9 (50%)
   Graft only 12 (57%) 5 (56%)
   Native artery only 9 (43%) 3 (33%)
   Both graft and native artery 0 (0%) 1 (11%)
   Multiple culprit lesions 2 (10%) 1 (11%)
  PCI at baseline and follow-up 17 (44%) 7 (39%)
  Thrombus aspiration 0 (0%) 1 (14%)
   Rotational atherectomy 3 (18%) 1 (14%)
   Intravascular ultrasound 2 (12%) 0 (0%)
   Distal protection device 2 (12%) 1 (14%)
BCIS indicates British Cardiovascular Intervention Society; and PCI, 
percutaneous coronary intervention.
*Median (interquartile range).
†Mean±SD.
‡≥1 overnight stay.
§Complication in invasive group (n=1) was worsening renal function 
postangiography.
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medical management was adopted. Fifteen (52%) par-
ticipants assigned to the medical group had an invasive 
procedure during the follow-up period, and 7 (47%) 
of these patients received PCI. Overall, 18 invasive pro-
cedures were performed in this group, and 7 (24%) 
patients were treated with PCI. None of the randomized 
patients received redo-CABG.
Health Outcomes
During ≈2-years’ follow-up (median [interquartile range] 
744 [570–853] days), the composite efficacy outcome 
of all-cause mortality, nonfatal MI, refractory ischemia, 
or HF hospitalization occurred in 13 (42%) participants 
in the invasive group and in 13 (45%) in the medical 
Table 5. Primary and Secondary Outcomes Over Follow-Up Period (≥18 Months; Median 744 [Interquartile Range 570–853] D)
Outcomes All (N=60) Invasive (N=31) Medical (N=29)
Hazard Ratio 
(95% CI)
Efficacy outcome     
  All-cause mortality, rehospitalization for refractory ischemia/angina, MI, 
or hospitalization for heart failure
26 (43%) 13 (42%) 13 (45%) 0.85 (0.39–1.83)
Safety outcome     
  Bleeding (BARC types 2–4),41 stroke, procedure-related type 4 MI, 
worsening renal function, or hemodialysis during the index hospitalization
17 (28%) 8 (26%) 9 (31%) 0.87 (0.34–2.25)
 Efficacy and safety outcomes (both) 10 (17%) 4 (13%) 6 (21%) 0.62 (0.17–2.19)
 Efficacy or safety outcomes (either) 33 (55%) 17 (55%) 16 (55%) 0.96 (0.48–1.90)
Components of the efficacy and safety outcomes     
  Death 8 (13%) 5 (16%) 3 (10%)  
   Cardiovascular* 2 (3%) 2 (6%) 0 (0%)  
   Noncardiovascular† 4 (7%) 2 (6%) 2 (7%)  
   Unknown cause 2 (3%) 1 (3%) 1 (3%)  
  Refractory ischemia 0 (0%) 0 (0%) 0 (0%)  
  Nonfatal MI‡ 22 (37%) 9 (29%) 13 (45%)  
  Heart failure 7 (12%) 4 (13%) 3 (10%)  
  Primary efficacy outcome at 12 mo 20 (33%) 10 (32%) 10 (34%)  
  Death at 12 mo 5 (8%) 4 (13%) 1 (3%)  
  Bleeding (BARC types 2–4) 11 (18%) 4 (13%) 7 (24%)  
  Stroke 0 (0%) 0 (0%) 0 (0%)  
  Procedure-related MI 0 (0%) 0 (0%) 0 (0%)  
  Worsening renal function 8 (13%) 5 (16%) 3 (10%)  
  Primary safety outcome at 12 mo 12 (20%) 7 (23%) 5 (17%)  
Secondary outcomes     
  Number of patients with serious adverse event 40 (67%) 20 (65%) 20 (69%)  
  Number of serious adverse events per patient§ 1 (0–2) 1 (0–3) 1 (0–2)  
  Number of patients with a rehospitalization (any reason) 39 (65%) 20 (65%) 19 (66%)  
  EQ-VAS health status 6 mo§ 75 (60–80) 80 (40–80) 75 (60–80)  
  EQ-5D-5L score 6 mo§ 0.82 (0.53–0.94) 0.67 (0.34–0.94) 0.89 (0.67–0.95)  
  EQ-VAS health status 12 mo§ 70 (50–80) 65 (50–80) 70 (50–80)  
  EQ-5D-5L score 12 mo§ 0.82 (0.62–0.95) 0.72 (0.56–0.94) 0.83 (0.72–0.95)  
  CCS angina class 6 mo§ 3.0 (1.0–4.0) 4.0 (1.0–5.0) 2.5 (1.0–3.0)  
  CCS angina class 12 mo§ 4.0 (3.0–5.0) 4.0 (4.0–5.0) 4.0 (3.0–5.0)  
None of the patients underwent redo coronary artery bypass graft surgery. BARC indicates Bleeding Academic Research Consortium; CCS, Canadian Cardiovascular 
Society; EQ-5D-5L, EuroQol 5 Dimensions 5 Levels; EQ-VAS, EuroQol Visual Analogue Scale; MI, myocardial infarction; and NSTEMI, non–ST-segment–elevation 
myocardial infarction.
*In invasive group: n=1 (death because of heart failure), n=1 (death because of subdural hemorrhage).
†In invasive group: n=1 (death because of multi-organ failure), n=1 (death because of lung cancer); in medical group, n=1 (death because of bladder cancer), n=1 
(death because of gastric malignancy).
‡In invasive group: n=5 (type 1 NSTEMI), n=3 (type 2 NSTEMI), n=1 (both types 1 and 2 NSTEMI); in medical group: n=10 (type 1 NSTEMI), n=2 (both types 1 and 
2 NSTEMI), n=1 (STEMI).
§Median (interquartile range).
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group (hazard ratio; 95% CI, 0.85 [0.39–1.83]; Table 5). 
Five participants died in the invasive group (2 cardiovas-
cular, 2 noncardiovascular, and 1 unknown cause) and 
3 died in the medical group (2 noncardiovascular and 1 
unknown cause).
The composite safety outcome of major bleeding 
(Bleeding Academic Research Consortium types 2–4), 
stroke, procedure-related MI, or worsening renal func-
tion occurred in 8 (26%) participants in the invasive group 
and in 9 (31%) participants in the medical group (haz-
ard ratio; 95% CI, 0.87 [0.34–2.25]; Table 5). Bleeding 
occurred in 4 (13%) and 7 (24%) patients in the invasive 
and medical groups, respectively. Worsening renal func-
tion occurred in 5 (16%) patients in the Invasive Group 
compared with 3 (10%) patients in the Medical Group.
Overall, 33 (55%) participants experienced at least 
one of these events: 17 (55%) of 31 participants in 
the invasive group and 16 (55%) of participants in 
the medical group (hazard ratio; 95% CI, 0.96 (0.48–
1.90). The Kaplan-Meier survival curves are shown in 
Figure 3. Overall, there were no differences between 
the groups. The time course for efficacy events 
appeared to differ between the groups with propor-
tionately more events occurring earlier in the medical 
group and proportionately more events occurring later 
in the invasive group.
Health Status
Compared with the medical group, the invasive group 
had higher degree of impairment in health-related 
quality of life (eg, lower EuroQol 5 Dimensions 5 Levels 
score) at baseline (Table 2) and 6 months, but by 12 
months, the average group scores were similar (Table 5).
Angina
Functional limitation from angina, reflected by the 
Canadian Cardiovascular Society angina class, was simi-
lar between the groups at 6 and 12 months.
DISCUSSION
This study informs the evidence gap relating to inva-
sive versus medical management in patients presenting 
with an acute NSTE-ACS and prior CABG. We report 
the first randomized, controlled, multicenter, trial of 
invasive and noninvasive management strategies in 
this patient group. The main findings are (1) enroll-
ment into the randomized trial was feasible but chal-
lenging (Figure  1; CONSORT diagram). The age and 
sex distributions of the patients in the trial and registry 
groups were similar, suggesting minimal selection bias; 
Figure 3. Kaplan-Meier survival curves for time to occurrence of the composite outcomes for efficacy and safety, by study group.
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(2) adherence to the randomized strategy within the 
30 day crossover period was achieved in all but one of 
the participants; (3) revascularization was initially per-
formed in only one-third of the invasive group; (4) the 
majority of the trial population experienced a major 
adverse event during follow-up; and (5) no between-
group differences in these events, but the trial was not 
powered for these. The trial provides proof-of-concept 
evidence that an initial noninvasive management strat-
egy in NSTE-ACS patients with prior CABG is feasible. 
Importantly, the results support the rationale for a sub-
stantive health outcome trial of these strategies in this 
patient group.
Patients with a prior CABG who present with an 
acute coronary syndrome have usually experienced 
chronic myocardial ischemia for years. In this study, 68% 
of participants had a prior MI. The cause of an NSTE-
ACS in patients with a prior CABG may be the eventual 
occlusion of a chronically diseased graft, a mismatch in 
myocardial blood supply:demand (type 2 MI) whereby 
collateral blood supply fails to meet myocardial demand 
or occlusion of a native coronary artery. The clinical case 
presented in our study (Figure 2) is 1 example. Chronic 
ischemia stimulates arteriogenesis promoting coronary 
collateral connections to deliver oxygenated blood to 
ischemic myocardium.44 These microconnections may 
be extensive and imperceptible at angiography.
In our study, a culprit vessel was only identified by 
the attending cardiologist in half of the invasively man-
aged patients. This conundrum reflects the diagnos-
tic uncertainties associated with complex, multivessel 
native coronary and bypass graft disease. PCI was ini-
tially performed in one-third of the invasive group. This 
may reflect uncertainties about performing complex 
PCI when the culprit lesion is not obvious and when 
procedural risks may be felt to be high. Further, multi-
morbidity may limit the potential for revascularization 
to improve quality of life. Finally, the overall risk:benefit 
ratio of performing PCI in this population may also be 
influenced by the fact that the participants had stabi-
lized with medical therapy. PCI was only performed in a 
minority of the invasive group.
Burden of Disease
In contemporary trials involving NSTE-ACS patients, the 
12-month major adverse cardiac event rate is usually 
8% to 10%. In our trial, the rate was over 4× higher 
(45% met either primary efficacy or safety outcomes 
at 12 months), increasing to 55% overall. The rising 
event rate over time contrasts with other trials in NSTE-
ACS populations in which major adverse cardiac event 
rates tend to plateau during the first 3 months post-
MI. The older age and universal presence of multimor-
bidity probably explain the differences in prognosis 
between NSTE-ACS patients with versus without prior 
CABG. Our results support the hypothesis that routine 
noninvasive management could be initially adopted for 
patients with an NSTE-ACS and prior CABG except in 
the minority with ongoing ischemia.
Advances in Interventional Management
In recent years, radial artery access has become the 
standard approach for invasive management rather 
than femoral artery access. The left radial artery allows 
access in patients with a left internal mammary artery 
graft. Adoption of advanced techniques for revascular-
ization of chronic native vessel occlusive disease might 
lead to higher rates of successful revascularization.45 
This possibility could be prospectively assessed in a 
larger multicenter trial.
Noninvasive Imaging
Functional imaging to elicit inducible ischemia, notably 
with stress cardiovascular magnetic resonance, echocar-
diography, or myocardial perfusion scintigraphy, may be 
useful. However, these tests may be logistically challeng-
ing to perform on an emergent basis. Computerized 
tomography coronary angiography is useful for imaging 
grafts but not necessarily for imaging native coronary 
arteries because calcification provokes artifacts, reduc-
ing diagnostic accuracy. For this reason, in our opinion, 
computerized tomography coronary angiography has 
limited clinical utility to provide a comprehensive diag-
nostic evaluation in this patient population.
Future Substantive Trial of Invasive 
Versus Noninvasive Management in 
Patients With a NSTE-ACS and Prior 
CABG
Some of the previous pivotal trials excluded patients 
with prior CABG (Table 1). The reasons for excluding 
these patients may be because of their distinct com-
plexities relating to occlusive native vessel coronary 
artery disease, graft disease, and concomitant health 
problems. Consequently, practice guidelines are not 
evidence based in this subgroup meaning that clinicians 
lack relevant information to inform decision-making.
One of the primary aims of our pilot trial was to 
provide information on whether a larger trial in this 
NSTE-ACS subgroup might be feasible. Adherence to 
the randomized strategy was achieved in all but one of 
the participants, indicating that the interventions were 
feasible. Half of the medical group subjects under-
went invasive angiography during follow-up but only a 
minority (24%) received PCI.
This study was logistically challenging to deliver. 
First, the grant committee raised concern about the 
ethics of randomizing study participants to noninvasive 
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management and rejected our application for fund-
ing. The results of our trial provide reassurance in this 
regard. Without core funding support, this study was all 
the more difficult to deliver. Screening and enrollment 
were time consuming. The population mainly included 
frail and elderly participants (mean age, 71±9 years; 
Table 2). Physician preference was a determining fac-
tor for enrollment. Over half of the patients screened 
were deemed ineligible for randomization based on 
physician preference. Our experience indicates that a 
multicenter phase 3 trial will present logistical chal-
lenges. To deliver that trial, support from physicians 
during urgent care will be needed. To that end, we 
hope that the preliminary evidence of similar adverse 
event rates between the groups will give physicians 
and patients confidence to participate. We envisage 
the future trial would be pragmatic, with an all-comers 
approach to enrollment and eligibility criteria similar to 
the pilot. We envisage a noninferiority design for inva-
sive versus noninvasive management and a primary 
composite outcome that includes all-cause mortality 
and spontaneous adverse events that are not deter-
mined by clinicians’ decisions to minimize bias. The 
trial will champion advanced interventional techniques 
for native vessel revascularization. If the noninferior-
ity hypothesis is confirmed, then noninvasive manage-
ment could be considered a default standard of care 
for medically stabilized patients.
Potential Impact of a Future Trial
About 1 in 10 NSTE-ACS patients have prior CABG. This 
rate is likely to remain stable in the coming years reflect-
ing sustained referrals for CABG in the past decade and 
increasing longevity. Our results support the hypothesis 
that a noninvasive strategy could be initially adopted 
for most NSTE-ACS patients with prior CABG, reserv-
ing invasive management for patients with persistent or 
recurrent, ischemia. The results from a future phase 3/4 
trial could be implemented in daily practice, potentially 
reducing variations in management, enabling more 
efficient resource utilization, and allowing NSTE-ACS 
patients with prior CABG to reach critical points in the 
care pathway more quickly.
Limitations
The sample size is insufficient to draw conclusions 
about the effectiveness of the clinical strategies. The 
study predates recent advances in interventional tech-
niques for chronic occlusive coronary artery disease.
Conclusions
In a pilot study, we observed no difference in clinical 
outcomes between patients with NSTE-ACS and prior 
CABG undergoing either noninvasive or routine invasive 
management. A randomized trial of these strategies 
is feasible. A substantive trial involving contemporary 
invasive and medical therapies seems warranted.
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